Results from US Government-Sponsored Phase 1 Trial of VSV Vaccine Reported
?An early-stage clinical trial of an experimental Ebola vaccine conducted at the National Institutes of Health (NIH) and the Walter Reed Army Institute of Research (WRAIR) found that the vaccine, called VSV-ZEBOV, was safe and elicited robust antibody responses in all 40 of the healthy adults who received it. The most common side effects were injection site pain and transient fever that appeared and resolved within 12 to 36 hours after vaccination. A report describing preliminary results of the NIH-WRAIR study appears online today in The New England Journal of Medicine. The VSV-ZEBOV candidate is one of two experimental Ebola vaccines now being tested in the phase 2/3 PREVAIL clinical trial that is enrolling volunteers in Liberia.
“The ongoing Ebola outbreak in West Africa is unprecedented in scope and duration,” said Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. “The outbreak is slowly coming under control, thanks to extraordinary and multi-faceted efforts in the affected nations. However, there still are no licensed specific therapies or vaccines for Ebola. Until a safe and effective vaccine is available, the world will continue to be under-prepared for the next Ebola outbreak.”
Scientists at the Public Health Agency of Canada developed the candidate vaccine. It was licensed to NewLink Genetics Corp. of Ames, Iowa, a company collaborating with Merck & Co. Inc., of Kenilworth, New Jersey, which is responsible for advancing this vaccine towards regulatory approval. The investigational vaccine is based on a genetically modified and attenuated vesicular stomatitis virus (VSV), a virus that mainly affects cattle. In the investigational vaccine, a gene for a VSV protein is replaced with a gene segment from a key protein in the Zaire species of Ebola virus. The vaccine does not contain the whole Ebola virus and therefore cannot infect vaccinated persons with Ebola.
The new report summarizes results of the first 52 volunteers enrolled in the study: 26 at the NIH Clinical Center in Bethesda, Maryland, and 26 at the WRAIR clinic in Silver Spring, Maryland. Six volunteers at each site received a placebo injection of saline solution, and the remaining 40 received the experimental vaccine at either one of two different dosages (2 x107 or 3 x106 in 20 volunteers at each site). The NIH trial was led by NIAID investigators Richard T. Davey, Jr., M.D., and John H. Beigel, M.D., while Jason A. Regules, M.D., and Stephen J. Thomas, M.D., headed the trial at WRAIR.
The candidate vaccine’s ability to stimulate immune responses was assessed by sampling the volunteers’ blood at multiple time points following injection. (The blood sampling schedule differed between the two trial sites.) Of those volunteers tested at 14 days after injection, 93 percent (26 out of 28) of whose who had received vaccine developed antibodies against Zaire species of Ebola virus. Antibodies were detected in the remaining 14 volunteers who had received vaccine by 28 days after injection. Antibody responses were approximately three-fold greater in those who received the higher vaccine dose. This information was available to the designers of the PREVAIL trial and was used to guide the decision to use VSV-ZEBOV at the higher dosage level in that trial.
“The prompt, dose-dependent production of high levels of antibodies following a single injection and the overall favorable safety profile of this vaccine make VSV-ZEBOV a promising candidate that might be particularly useful in outbreak interventions,” said Dr. Davey.
The Latest on: Ebola Vaccine
via Google News
The Latest on: Ebola Vaccine
- Thank God for ingenious coronavirus vaccine - we must now deal with political challengeon December 3, 2020 at 10:03 am
It was just over a year ago, November 2019, that the world learned of the coronavirus outbreak in China. By March 2020, the World Health Organisation (WHO) ...
- Astral Aviation Readies to Perform Vaccine Flights within Africaon November 30, 2020 at 6:35 am
Astral Aviation has announced that it is ready to support the distribution of the recently discovered COVID-19 vaccines across its scheduled network of destinations within Africa.
- Astral Aviation ready to transport vaccines to and within Africaon November 26, 2020 at 7:12 am
Kenya’s Astral Aviation is ready to support the distribution of Covid-19 vaccines to and within Africa. The Nairobi-hubbed airline, operating a fleet of ...
- With global push for COVID-19 vaccines, China aims to win friends and cut dealson November 25, 2020 at 9:50 am
Read our COVID-19 research and news. Beijing-based Sinovac, which makes a COVID-19 vaccine from inactivated virus, has efficacy trials underway in Brazil, Turkey, and Indonesia—but not in China. The ...
- Vaccines Won't Stop the Pandemic Unless at Least 50 Million Skeptical Americans Change Their Mindson November 23, 2020 at 2:25 am
"In Ghana, two Ebola vaccine trials were suspended because of widespread anxiety ... speak virtually with the Covid-19 Advisory Council during a briefing on November 9, 2020 in Wilmington, Delaware.
- Congo announces end to its 11th deadly Ebola outbreakon November 18, 2020 at 2:31 am
KINSHASA, Congo — Congo has declared an end to its 11th Ebola outbreak, this one in western Equateur province, nearly six months after cases were reported and amid the rise of COVID-19 in the ...
- Poorer nations face wait for Covid-19 vaccine as West locks down supplyon November 18, 2020 at 12:07 am
Food storage containers, for example, are regularly cooled to close to the temperature required by the vaccine before being shipped long distances. And the Ebola vaccine, which like those in trial ...
- Covid: 6,000 UK volunteers to be injected with vaccine in phase 3 trialon November 16, 2020 at 12:38 am
9 All those 50 and over ... The same virus forms the backbone of a recently approved Ebola vaccine, deployed during the 2019 outbreak in the Democratic Republic of the Congo.
- Ebola Vaccine Market Comprehensive and Analytical Business Analysis, Forecast Till 2029 | Sarepta Therapeutics Inc and Mapp Biopharmaceutical Incon November 13, 2020 at 12:43 am
MarketResearch.Biz :Ebola Vaccine Market Overview: The report provides each quantitative and qualitative information on the global Ebola Vaccine market for the period of 2020 to 2029. Given the ...
via Bing News